CAPR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	210 171
Vidutinė apimtis	329 747
Rinkos kapitalizacija	165.08M
EPS	$0 ( 2024-02-29 )
Kita pelno data	( $-0.110 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.31
ATR14	$0.0140 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Collier Earl M Jr	Buy	30 000	Common Stock
2024-04-23	Collier Earl M Jr	Sell	30 000	Stock Option (Right to Buy)
2024-04-23	Musket David B	Buy	16 156	Common Stock
2024-04-23	Musket David B	Sell	5 750	Stock Option (Right to Buy)
2024-01-02	Kelliher Mike	Buy	30 000	Stock Option (Right to Buy)

INSIDER POWER
79.03
Last 97 transactions
Buy: 2 824 525 \| Sell: 392 146

Tūris Koreliacija

Ilgas: -0.32 (neutral)

Trumpas: -0.56 (weak negative)

Signal:(52.815) Neutral

Capricor Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
QNST	0.827
LPTH	0.822
MNDY	0.811
CLMT	0.805

10 Labiausiai neigiamai susiję koreliacijos
LMST	-0.823
NVEI	-0.82

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Capricor Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.53
( weak )

0.50
( neutral )

0.00
( neutral )

0.56
( weak )

-0.39
( neutral )

-0.43
( neutral )

Capricor Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$25.18M
Bruto pelnas:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2023
Pajamos:	$25.18M
Bruto pelnas:	$24.11M (95.75 %)
EPS:	$-0.830

FY	2022
Pajamos:	$2.55M
Bruto pelnas:	$1.85M (72.74 %)
EPS:	$-1.180

FY	2021
Pajamos:	$245.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.000867

Financial Reports:

No articles found.

Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.